Auris Medical Holding AG (NASDAQ:EARS) saw an uptick in trading volume on Wednesday . 13,574 shares were traded during trading, a decline of 100% from the previous session’s volume of 3,200,224 shares.The stock last traded at $0.62 and had previously closed at $0.69.

Several research firms have recently commented on EARS. ValuEngine raised shares of Auris Medical from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Eurobank EFG began coverage on shares of Auris Medical in a research report on Monday, October 8th. They set a “buy” rating and a $2.50 price target for the company.

The stock has a market cap of $3.08 million, a P/E ratio of -0.11 and a beta of -1.09.

Auris Medical (NASDAQ:EARS) last released its quarterly earnings results on Thursday, November 15th. The biotechnology company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.03). Analysts predict that Auris Medical Holding AG will post -0.48 EPS for the current year.

An institutional investor recently bought a new position in Auris Medical stock. Bellevue Group AG bought a new position in Auris Medical Holding AG (NASDAQ:EARS) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 193,125 shares of the biotechnology company’s stock, valued at approximately $151,000. Bellevue Group AG owned approximately 3.16% of Auris Medical at the end of the most recent quarter. Hedge funds and other institutional investors own 20.18% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at

Auris Medical Company Profile (NASDAQ:EARS)

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.

Read More: Buyback For Investors Defined

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with's FREE daily email newsletter.